

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number  
**WO 2005/016954 A2**

(51) International Patent Classification<sup>7</sup>: **C07K**

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: **PCT/US2004/026236**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 10 August 2004 (10.08.2004)

English

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**60/495,035 14 August 2003 (14.08.2003) US**

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant: **BOSTON MEDICAL CENTER CORPORATION [US/US]**; One Boston Medical Center Place, Boston, MA 02118 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SAUBERMANN, Lawrence, J. [US/US]**; 15 Saddle Ridge Road, Dover, MA 02030 (US). **FARRAYE, Francis, A. [US/US]**; 8 Copperwood Road, Medfield, MA 02052 (US). **MORALES, Victor, M. [US/US]**; 8 Broad Street, Hollis, NH 03049 (US).

(74) Agents: **HEINE, Holliday, C. et al.**; Weingarten, Schurigin, Gagnebin & Lebovici, LLP, Ten Post Office Square, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): **AE, AG, AL, AM,**

**WO 2005/016954 A2**

(54) Title: **IMMUNOLOGIC ACTIVITY MEASURE(S) FOR T "HELPER" ON-ASSOCIATED CONDITIONS**

(57) Abstract: A method of providing a reproducible and clinically relevant disease activity measurement for a group of immunologic disorders that share features of a T "helper" 1 (Th1) immune activation phenotype is disclosed. Th1 responses are characterized by the release of a set of pro-inflammatory substances by white blood cells (WBC). By evaluating the *ex vivo* activation response of whole blood in terms of the extent of release of Th1 produced pro-inflammatory substances in blood (i.e., WBC activity) following activation with a Th1-associated stimulant, the level of, e.g., disease activity or immunosuppression in a specific individual can be determined. The method of the invention provides a disease activity marker for a wide variety of Th1 inflammatory responses, including Crohn's Disease, psoriasis, rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), multiple sclerosis and solid organ transplant rejection.